Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ENDRA Life Sciences (NDRA) Cash & Equivalents: 2016-2021

Historic Cash & Equivalents for ENDRA Life Sciences (NDRA) over the last 6 years, with Sep 2021 value amounting to $11.8 million.

  • ENDRA Life Sciences' Cash & Equivalents rose 210.90% to $11.8 million in Q3 2021 from the same period last year, while for Sep 2021 it was $11.8 million, marking a year-over-year increase of 210.90%. This contributed to the annual value of $7.2 million for FY2020, which is 17.06% up from last year.
  • Latest data reveals that ENDRA Life Sciences reported Cash & Equivalents of $11.8 million as of Q3 2021, which was down 16.02% from $14.0 million recorded in Q2 2021.
  • In the past 5 years, ENDRA Life Sciences' Cash & Equivalents registered a high of $16.8 million during Q1 2021, and its lowest value of $133,679 during Q1 2017.
  • In the last 3 years, ENDRA Life Sciences' Cash & Equivalents had a median value of $3.9 million in 2019 and averaged $6.6 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first skyrocketed by 9,136.41% in 2017, then plummeted by 90.87% in 2018.
  • Over the past 5 years, ENDRA Life Sciences' Cash & Equivalents (Quarterly) stood at $5.6 million in 2017, then grew by 15.52% to $6.5 million in 2018, then dropped by 4.59% to $6.2 million in 2019, then rose by 17.06% to $7.2 million in 2020, then surged by 210.90% to $11.8 million in 2021.
  • Its last three reported values are $11.8 million in Q3 2021, $14.0 million for Q2 2021, and $16.8 million during Q1 2021.